Johnson & Johnson to Participate in Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
Johnson & Johnson to Participate in Goldman Sachs 42nd Annual Global Healthcare Virtual Conference | Johnson & Johnson Skip to
Read morePharmaceutical Company News
The latest news from the pharmaceutical sector. Covering the latest breaking news, encompassing company news from leading pharmaceutical companies and related companies.
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 Vaccine
NEW YORK & MAINZ, Germany–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a Biologics License Application
Read moreGSK and Vir Biotechnology announce the start of the EMA rolling review of VIR-7831 (sotrovimab) for the early treatment of COVID-19 | GSK
For media and investors only Issued: London UK and San Francisco US Rolling review will evaluate sotrovimab in adults and
Read moreImfinzi and tremelimumab with chemotherapy demonstrated overall survival benefit in POSEIDON trial for 1st-line Stage IV non-small cell lung cancer
7 May 2021 07:00 BST First Phase III trial to demonstrate overall survival benefit with tremelimumab Imfinzi plus chemotherapy demonstrated
Read moreAmgen To Present At The 2021 Bank of America Merrill Lynch Healthcare Conference
THOUSAND OAKS, Calif., May 6, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare
Read more20210506 CSL Behring Announces Global Commercialization and License Agreement with uniQure
KING OF PRUSSIA, PA, USA: Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License
Read moreEisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma | News Release：2021
TOKYO and KENILWORTH, N.J., May 6, 2021 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck &
Read moreTakeda to Hold Fourth Quarter and Full-Year FY2020 Earnings Conference Calls I Takeda
CAMBRIDGE, Mass. & OSAKA, Japan, May 6, 2021 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host a series of conference calls on May
Read morePfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
NEW YORK & MAINZ, Germany–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of
Read moreSanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research Projects led by collaborating researchers from the two organizations
Read moreMay 06,2021 | Research Collaboration by Chugai, the University of Tokyo and RIKEN on Functional Genome Database Published in Cell | News | CHUGAI PHARMACEUTICAL CO., LTD.
“Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases” (https://www.sciencedirect.com/science/article/pii/S0092867421004293) “Chugai’s innovation is generated by its own scientific and
Read moreFDA Accepts Amgen’s Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
THOUSAND OAKS, Calif., May 5, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for
Read moreEuropean Commission approves Benlysta for adult patients with active lupus nephritis | GSK
For media and investors only Issued: London, UK GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded
Read moreRoche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study Tecentriq
Read moreWorld Asthma Day 2021 | Novartis
Today is World Asthma Day, when people across the asthma community come together to raise awareness of the challenges being
Read moreViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV | GSK
For media and investors only Issued: London UK ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc
Read moreFighting MS through innovation | Novartis
Amid the coronavirus pandemic, concern has grown over the potential neglect of other serious diseases. Multiple sclerosis (MS), for example,
Read moreMerck-News | Merck
04 May 2021 | Darmstadt, Germany Today, May 4, 2021, Merck has published the following ad hoc news: Disclosure of
Read moreJohnson & Johnson to Participate in Bernstein’s 37th Annual Strategic Decisions Virtual Conference
Johnson & Johnson to Participate in Bernstein’s 37th Annual Strategic Decisions Virtual Conference | Johnson & Johnson Skip to content
Read moreFrom melanoma survivor to front-line nurse
[unable to retrieve full-text content]
Read moreMallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Keratitis at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
DUBLIN, May 3, 2021 /PRNewswire/ — Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced data from its Phase 4,
Read moreSandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine | Novartis
Sandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study1 Neovascular
Read moreNovartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept | Novartis
In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual
Read more20210501 Update on CSL COVID-19 Vaccine Manufacturing Numbers
Melbourne, Australia: CSL can confirm that production of the AstraZeneca COVID-19 vaccine for Australia has reached more than a million
Read moreFarxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes
30 April 2021 22:00 BST Approval is the most significant advancement in the treatment of chronic kidney disease in more
Read more